These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 8558517

  • 21. [PAF-antagonists with phospholipid structure. 3. Phospholipids with heterocyclane head groups and variations of the phosphorus-nitrogen distance; synthesis, characterization and structure-activity relationship].
    Kertscher HP, Ostermann G.
    Pharmazie; 1991 Nov; 46(11):772-4. PubMed ID: 1811226
    [Abstract] [Full Text] [Related]

  • 22. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
    Devadas B, Freeman SK, Zupec ME, Lu HF, Nagarajan SR, Kishore NS, Lodge JK, Kuneman DW, McWherter CA, Vinjamoori DV, Getman DP, Gordon JI, Sikorski JA.
    J Med Chem; 1997 Aug 01; 40(16):2609-25. PubMed ID: 9258368
    [Abstract] [Full Text] [Related]

  • 23. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
    Terashita Z, Imura Y, Takatani M, Tsushima S, Nishikawa K.
    J Pharmacol Exp Ther; 1987 Jul 01; 242(1):263-8. PubMed ID: 3612533
    [Abstract] [Full Text] [Related]

  • 24. [Synthesis and platelet aggregation inhibitory activity of analogues of 4-([2-(1H-imidazol-1-yl)-1-(4-substituted-phenyl)ethoxy]methyl)benzoic acids].
    Wu QY, Yang JQ.
    Yao Xue Xue Bao; 1991 Jul 01; 26(10):741-6. PubMed ID: 1823715
    [Abstract] [Full Text] [Related]

  • 25. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework.
    Abe Y, Kayakiri H, Satoh S, Inoue T, Sawada Y, Imai K, Inamura N, Asano M, Hatori C, Katayama A, Oku T, Tanaka H.
    J Med Chem; 1998 Feb 12; 41(4):564-78. PubMed ID: 9484506
    [Abstract] [Full Text] [Related]

  • 26. Novel arylpyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides as inhibitors of platelet aggregation. 1. Synthesis and pharmacological evaluation.
    Campillo N, García C, Goya P, Páez JA, Carrasco E, Grau M.
    J Med Chem; 1999 May 20; 42(10):1698-704. PubMed ID: 10346922
    [Abstract] [Full Text] [Related]

  • 27. [PAF-antagonists with lipid structure. 6. Alkylpropandiol lipids with acyl- and ether- structures at the C-3 position and heterocyclic head groups; synthesis, characterization and structure-activity relationship].
    Kertscher HP.
    Pharmazie; 1997 Sep 20; 52(9):672-5. PubMed ID: 9411454
    [Abstract] [Full Text] [Related]

  • 28. Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
    Parlow JJ, Burney MW, Case BL, Girard TJ, Hall KA, Hiebsch RR, Huff RM, Lachance RM, Mischke DA, Rapp SR, Woerndle RS, Ennis MD.
    Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4657-63. PubMed ID: 19604694
    [Abstract] [Full Text] [Related]

  • 29. 1,5-Benzodiazepines. X. Dialkylamino substituted 1,5-benzodiazepine and [1,2,4]triazolo [4,3-a][1,5] benzodiazepine derivatives with inhibitory activity on PAF-induced platelet aggregation.
    Di Braccio M, Roma G, Grossi GC, Leoncini G, Maresca M.
    Farmaco; 1992 Jan 15; 47(1):77-90. PubMed ID: 1616579
    [Abstract] [Full Text] [Related]

  • 30. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K, Shimazaki T, Aoki Y, Yamashita H, Tanaka E, Banba S, Yazawa K, Kibayashi K, Banno H.
    J Med Chem; 1998 Oct 08; 41(21):4036-52. PubMed ID: 9767641
    [Abstract] [Full Text] [Related]

  • 31. 4-substituted 2-alkoxytetrahydrofurans as potent and long-lasting PAF antagonists.
    Carceller E, Merlos M, Giral M, Bartrolí J, García-Rafanell J, Forn J.
    J Med Chem; 1992 Feb 21; 35(4):676-83. PubMed ID: 1542094
    [Abstract] [Full Text] [Related]

  • 32. Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412.
    Handley DA, Van Valen RG, Melden MK, Houlihan WJ, Saunders RN.
    J Pharmacol Exp Ther; 1988 Nov 21; 247(2):617-23. PubMed ID: 3183958
    [Abstract] [Full Text] [Related]

  • 33. Pharmacological profile of epiyangambin: a furofuran lignan with PAF antagonist activity.
    Castro-Faria-Neto HC, Martins MA, Silva PM, Bozza PT, Cruz HN, de Queiroz-Paulo M, Kaplan MA, Cordeiro RS.
    J Lipid Mediat; 1993 May 21; 7(1):1-9. PubMed ID: 8358020
    [Abstract] [Full Text] [Related]

  • 34. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
    Vacher B, Bonnaud B, Funes P, Jubault N, Koek W, Assié MB, Cosi C, Kleven M.
    J Med Chem; 1999 May 06; 42(9):1648-60. PubMed ID: 10229633
    [Abstract] [Full Text] [Related]

  • 35. PAF-induced platelet aggregation ex vivo as a method for monitoring pharmacological activity in healthy volunteers.
    Adamus WS, Heuer H, Meade CJ.
    Methods Find Exp Clin Pharmacol; 1989 Jun 06; 11(6):415-20. PubMed ID: 2747341
    [Abstract] [Full Text] [Related]

  • 36. In vitro platelet-activating factor receptor binding inhibitory activity of pinusolide derivatives: a structure-activity study.
    Han BH, Yang HO, Kang YH, Suh DY, Go HJ, Song WJ, Kim YC, Park MK.
    J Med Chem; 1998 Jul 02; 41(14):2626-30. PubMed ID: 9651167
    [Abstract] [Full Text] [Related]

  • 37. (Pyridylcyanomethyl)piperazines as orally active PAF antagonists.
    Carceller E, Almansa C, Merlos M, Giral M, Bartrolí J, García-Rafanell J, Forn J.
    J Med Chem; 1992 Oct 30; 35(22):4118-34. PubMed ID: 1433215
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. 2-(3-Pyridyl)thiazolidine-4-carboxamides. 1. Novel orally active antagonists of platelet-activating factor (PAF).
    Nagaoka H, Hara H, Suzuki T, Takahashi T, Takeuchi M, Matsuhisa A, Saito M, Yamada T, Tomioka K, Mase T.
    Chem Pharm Bull (Tokyo); 1997 Oct 30; 45(10):1659-64. PubMed ID: 9353894
    [Abstract] [Full Text] [Related]

  • 40. Structure-activity relationship studies on chalcone derivatives: potent inhibition of platelet aggregation.
    Ko HH, Hsieh HK, Liu CT, Lin HC, Teng CM, Lin CN.
    J Pharm Pharmacol; 2004 Oct 30; 56(10):1333-7. PubMed ID: 15482650
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.